Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150

WVNews | Business

Feb 21, 2019

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 20, 2019--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developi…